A Randomised, Controlled, Phase 1 Study in Healthy Adults to Evaluate the Immunogenicity and Safety of a Recombinant H7 Hemagglutinin Influenza Vaccine
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 May 2018
At a glance
- Drugs PanBlok (Primary) ; ADVAX
- Indications Influenza A virus H7N9 subtype
- Focus Pharmacodynamics
- Sponsors Vaxine
- 04 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
- 04 May 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Feb 2017 New trial record